Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen |
| |
| Authors: | von Hentig Nils Kaykhin Pavel Stephan Christoph Babacan Errol Stürmer Martin Staszewski Schlomo Lötsch Jörn |
| |
| Affiliation: | Pharmazentrum Frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. Hentig@em.uni-frankfurt.de |
| |
| Abstract: | The human immunodeficiency virus protease inhibitor combination of atazanavir (ATV)-lopinavir-ritonavir was reported to exhibit a mutual pharmacoenhancement of plasma lopinavir and ATV concentrations which may be beneficial for salvage patients. We identified 17 patients in our pharmacokinetic database taking this combination and found conflicting results. Plasma concentrations of both ATV and lopinavir were modestly, although not significantly, decreased when the drugs were coadministered. Therefore, patients should be selected carefully for this regimen and frequent clinical and therapeutic drug monitoring is strongly advised. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
